John is a Member in the firm’s Corporate & Securities Section and its Life Sciences group. His practice includes the representation of a range of start-up and late-stage biotechnology and pharmaceutical companies, both private and public. He has extensive experience in venture capital financing, private placements, mergers and acquisitions, public offerings, and general corporate matters. In addition, he specializes in the structuring and negotiation of collaborative research and development transactions, strategic alliances, joint ventures, supply and distribution agreements and technology licensing transactions.
John spends a significant part of his practice representing international biotechnology clients in all aspects of their business. He has worked in particular with start-up and leading biotechnology companies in Germany France and Israel.
Recent representative transactions include the following:
Represented Intarcia Therapeutics in the negotiation of a strategic partnership involving the grant to Servier of an exclusive license to develop and commercialize ITCA 650, Intarcia’s phase 3 investigational therapy for the treatment of type 2 diabetes, in countries outside of the United States and Japan. Under the terms of the transaction, Servier agreed to pay Intarcia up front and development, regulatory and sales milestone payments totaling more than $1 billion. Intarcia will also receive ex-U.S./Japan tiered sales-related payments. The parties also agreed to share certain global development-related investments for ITCA 650.
Represented Mimetogen Pharmaceuticals in the negotiation of an exclusive license with a global pharmaceutical company under which Mimetogen granted the pharmaceutical company an exclusive license to develop and commercialize tavilermide for the treatment of dry eye disease.
Represented AVEO Oncology in the negotiation of an exclusive license agreement involving the grant to CANbridge Life Sciences of worldwide rights, excluding the United States, Canada, and Mexico, to AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate. CANbridge Life Sciences agreed to pay AVEO upfront and potential reimbursement and milestone payments upon the achievement of specified development, regulatory and commercialization objectives. AVEO is also eligible for a tiered royalty, ranging from a low double-digit up to a low-teen percent on net sales of AV-203 in the applicable territories.
In addition, John has served as both company counsel and underwriter’s counsel on initial public offerings, follow-on offerings, and PIPE financing transactions involving a number of biotechnology and medical device companies.
Articles in the National Law Review database by John J. Cheney